The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno, MD, PhD, of the Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, gives an overview of the Phase III iLLUMINATE trial (NCT02264574), which showed an improved progression-free survival, as well as higher response rates with ibrutinib-obinutuzumab vs. chlorambucil-obinutuzumab as a first-line treatment for chronic lymphocytic Leukemia (CLL). Dr Moreno also introduces other studies investigating various combinations with ibrutinib, including venetoclax and CAR T-cells, pushing towards better CLL treatments compared with the current standard of care. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
